Ohio will receive $7.2 million after improper Claritin rebates.

Schering-Plough Corp. will award Ohio $7.2 million after the company failed to reimburse the state's Medicaid program. According to federal law, Medicaid is supposed to receive the best price for a specific drug from pharmaceutical companies. Schering-Plough failed to perform proper rebates on the allergy medication Claritin.

Since the company neglected to factor discounts it had provided to two HMOs before it reported Claritin's best price, many states throughout the country received millions less in rebates. These prices were reported to the Centers for Medicare and Medicaid Services.

Medicaid programs in 49 states, including the District of Columbia, will receive $140.8 million from Schering-Plough. State and federal governments will also receive $282.3 million.

To read this article in full text, visit:

http://columbus.bizjournals.com/columbus/stories/2004/07/26/daily45.html?jst=b_ln_hl